<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
  <title>Thomas O. Kleen, Ph.D. - LinkedIn </title>
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
  <link href="http://www.linkedin.com/favicon.ico" rel="shortcut icon" type="image/ico" />
  
    <meta name="description" content="View Thomas O. Kleen, Ph.D.'s professional profile on LinkedIn.  LinkedIn is the world's largest business network, helping professionals like Thomas O. Kleen, Ph.D. discover inside connections to recommended job candidates, industry experts, and business partners." />

  
  
  

        <link rel="stylesheet" type="text/css" href="http://static.linkedin.com/scds/concat/common/build-517_4_3411-prod/css?f=css%2Fchrome&amp;f=css%2Fpublic_profile&amp;f=css%2Fpublic-profile%2Fdefault" />
    
</head>
<body id="www-linkedin-com" class="en public-profile">

<script type="text/javascript">document.body.className += " js";</script>
  
<div class="hresume">
    <div class="profile-header">
      <div class="masthead vcard contact portrait">
        <div id="nameplate">
          <h1 id="name"><span class="fn n"><span class="given-name">Thomas O.</span> <span class="family-name">Kleen, Ph.D.</span></span></h1>
        </div>
        <div class="content">
          <div class="info">
              <div class="image"><img src="http://media.linkedin.com/mpr/mpr/shrink_80_80/p/2/000/047/143/1a99bed.jpg" class="photo" alt="Thomas O. Kleen, Ph.D." /></div>
              <p class="headline title">
                
      Director, Business and Technology Development at Cellular Technology Limited
    
              </p>
            <div class="adr">
              <p class="locality">
                
      Cleveland/Akron, Ohio Area
    
              </p>
            </div>
          </div>
          <div class="actions">
            <ul>
              <li id="send-inmail">
                <a href="http://www.linkedin.com/ppl/webprofile?action=ctu&amp;id=26894133&amp;pvs=pp&amp;authToken=vQDT&amp;authType=name&amp;trk=ppro_cntdir&amp;lnk=cnt_dir" rel="nofollow">Contact Thomas O. Kleen, Ph.D.</a>
              </li>
              <li id="add-to-network">
                <a href="http://www.linkedin.com/ppl/webprofile?action=ctu&amp;id=26894133&amp;pvs=pp&amp;authToken=vQDT&amp;authType=name&amp;trk=ppro_getintr&amp;lnk=cnt_dir" rel="nofollow">Add Thomas O. Kleen, Ph.D. to your network</a>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  <div id="main">
        <div id="overview">
          <dl>
              <dt>Current</dt>
              <dd>
                <ul class="current">
                        <li>




            
      Director, Business and Technology Development
    
        at
            <a href="http://www.linkedin.com/companies/cellular-technology-ltd%2E" >Cellular Technology Limited</a>
                        </li>
                </ul>
              </dd>
              <dt>Past</dt>
              <dd>
                <ul>
                        <li>




            
      Director, Assay Development &amp; Scientific Liaison
    
 at Cellular Technology Limited
                        </li>
                        <li>




            
      Co-Founding Scientist &amp; Consultant
    
 at Cellular Technology Limited
                        </li>
                </ul>
              </dd>
              <dt>Education</dt>
              <dd>
                <ul>
                      <li>
                        
           Julius-Maximilians-Universit&#xe4;t W&#xfc;rzburg
      
                      </li>
                      <li>
                        
           Case Western Reserve University
      
                      </li>
                      <li>
                        
           New Zealand Forest Research, Department of Molecular Genetics, Rotorua, New Zealand
      
                      </li>
                </ul>
                  <div class="showhide-block" id="moreedu">
                    <ul>
                          <li>
                            
           German Primate Center (DPZ), G&#xf6;ttingen, Germany
      
                          </li>
                          <li>
                            
           Universit&#xe4;t Bremen
      
                          </li>
                    </ul>
                    <p class="seeall showhide-link"><a href="#" id="moreedu-hide">see less...</a></p>
                  </div>
                      <p class="seeall showhide-link"><a href="#" id="moreedu-show">2 more...</a></p>
              </dd>
              <dt class="connections">Connections</dt>
              <dd class="connections">
                <img src="http://static.linkedin.com/scds/common/u/img/icon/conx/icon_conx_14_24x24.gif" width="24" height="24" alt="" />
                <strong class="connection-count">
                120
                </strong> connections
              </dd>

              <dt>Industry</dt>
              <dd>
                Biotechnology
              </dd>
            
              <dt>Websites</dt>
              <dd>
                <ul>
                    <li>
                          <a href="http://www.immunospot.com" class="url" rel="nofollow" target="_blank">
                            My Company
                          </a>
                    </li>
                </ul>
              </dd>
          </dl>
        </div>
        <hr />
        






  <div id="summary">
    <h2>Thomas O. Kleen, Ph.D.&#8217;s Summary</h2>
    
      <p class="summary">
        Dr. Kleen is currently Director of Business and Technology Development at Cellular Technology Limited (CTL).  Prior to this position, he was Director of Assay Development at CTL.  Dr. Kleen received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University W&#xfc;rzburg, Bavaria, Germany. He co-founded CTL during his studies at Case Western Reserve University in Cleveland, Ohio, where he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections. He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematological disorders after treatment with full myelo-ablative regimens<br>
<br>
His main expertise is in immunology, adjuvants and vaccine evaluation with a focus on high sensitivity T cell immune monitoring of novel vaccines and to detect adverse immune reactions to gene therapy and protein based drugs early.  He spends significant time educating pharmaceutical entities and governmental agencies about validated, GLP compliant technologies, that are available today, for Immune Monitoring during pre clinical and clinical trials.  <br>
<br>
A increasing number of new innovative, vaccines aim to elicit a response from the cellular components of the immune system, therefore the U.S. FDA recently emphasized a need for better prognostic models and the establishment of correlates of protection for novel vaccines that aim to elicit cell mediated immunity (CMI).  <br>
<br>
Dr. Kleen is currently faculty member of iSBTc-FDA Taskforce on Immunotherapy Biomarkers (http://www.isbtc.org/initiatives/#1), which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.
      </p>
    
    
      <h3>Thomas O. Kleen, Ph.D.&#8217;s Specialties:</h3>
      <p class="skills">
        Business development in the life sciences industry, strategic development, scientific consulting, novel technology evaluation, customer relationship management, and the ability to lead, coordinate and work seamlessly across multiple cross-functional teams to drive results.<br>
<br>
Scientific Consultation:<br>
Immune Monitoring, Immunology, Virology.
      </p>
    
  </div>
  <hr />







  <div id="experience">
    <h2>Thomas O. Kleen, Ph.D.&#8217;s Experience</h2>
    <ul class="vcalendar">
      
        
          


<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Director, Business and Technology Development
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/cellular-technology-ltd%2E?trk=ppro_cprof&amp;lnk=vw_cprofile" >Cellular Technology Limited</a></h4>
  <p class="organization-details">(Privately Held; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-01-01">January 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2010-06-20">Present</abbr>        <abbr class="duration" title="P2Y6M">(2 years 6 months)</abbr>
  </p>
    <p class="description">Identified, evaluated and developed new growth opportunities for CTL Contract Research Operations (CRO) and Consumables business with 80+ pharmaceutical, biotech and academic organizations, contributing to gross CRO revenue growth of 40% in 2008 and 55% in 2009.<br>
<br>
Informed pharmaceutical entities and governmental agencies through scientific presentations and training seminars about progress on validated, high-throughput immune monitoring technologies, especially for Cell Mediated Immunity (CMI), in Good Laboratory Practice (GLP)-compliant facilities according to US Code of Federal Regulations (CFR) Title 21 Part 58 for pre-clinical and phase 1 through 3 clinical trials.<br>
<br>
Initiated, consulted and participated in the conception and writing of multiple Business and Technical Contract Proposals with a combined value of more then 54 million dollars.<br>
<br>
Consulted C-Level executives and other decision makers in planning and execution of preclinical and/or clinical development strategies for drugs and/or vaccines that could benefit from CMI monitoring, specially regarding high sensitivity immune monitoring of novel vaccines, gene therapy, protein or peptide based drugs, that requires the ability to measure low frequency responses of T-cells.<br>
<br>
Supported strategic development, diversification and growth of the company from its inception as an image analysis instrumentation company for biomedical research to a business with a diverse range of products and services, including but not limited to ImmunoSpot and BioSpot software and instrumentation, scientific consultation services, consumables and contracted research services with an emphasis on high-throughput GLP-compliant immune monitoring of CMI for pre-clinical and clinical trials.  <br>
<br>
Throughout my tenure, the company has grown from a handful to over 55 employees, with headquarters in the USA and subsidiaries in China, Hungary and Germany (www.immunospot.com).</p>
</li>
        
      
      
        
          


<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Director, Assay Development &amp; Scientific Liaison
    
      </h3>
      <h4 class="org summary">Cellular Technology Limited</h4>
  <p class="organization-details">(Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003-02-01">February 2003</abbr>
 &mdash; <abbr class="dtend" title="2007-12-01">December 2007</abbr>        <abbr class="duration" title="P4Y11M">(4 years 11 months)</abbr>
  </p>
    <p class="description">Developed and tested procedures for product development, including large-scale cryopreservation and testing of human PBMC for commercial use and clinical trials, development, testing and manufacturing of serum-free media, as well as the composition, testing and manufacturing of ELISPOT kits.<br>
<br>
Supervised availability and management of materials, facilities, and personnel to support all laboratory studies performed by CTL&#x2019;s R&amp;D laboratory, including ensuring that equipment is appropriately maintained, and that Project Leaders completed their Test Plans prior to experimentation and that Test Reports were approved prior to presenting data to CTL Management. <br>
<br>
Enabled adaptation of new GLP-compliant high-throughput assays and procedures for testing of human and animal cell material in pre-clinical and phase 1 through 3 clinical trials.<br>
<br>
Coordinated with Quality Assurance to develop a quality system that increased operational efficiency and heightened regulatory compliance within CTL&#x2019;s GLP-compliant facility according to CFR Title 21 Part 58.  <br>
<br>
Reviewed and provided comments and suggestions on Standard Operation Procedures (SOPs), training materials, forms/templates, etc.<br>
<br>
Identified and evaluated relevant grant and contract solicitations with the U.S. government and presented them to management based on priority and potential.<br>
<br>
Consulted and participated in the conception and writing of multiple successful contract research proposals to government and pharmaceutical entities resulting in contracts with a combined value of 12 million dollars.<br>
<br>
Consulted on area of expertise to government, industrial and academic customers, nationally and internationally, through over fifteen scientific presentations and training seminars, including seminars in the USA, Australia, Brazil, Germany, South Africa, Singapore and Thailand.<br>
<br>
Established distributors for CTL products and services in the south-east Asia region, including Singapore, Malaysia, and Thailand.</p>
</li>
        
          


<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-Founding Scientist &amp; Consultant
    
      </h3>
      <h4 class="org summary">Cellular Technology Limited</h4>
  <p class="organization-details">(Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1999-10-01">October 1999</abbr>
 &mdash; <abbr class="dtend" title="2003-02-01">February 2003</abbr>        <abbr class="duration" title="P3Y5M">(3 years 5 months)</abbr>
  </p>
    <p class="description">Co-founded CTL and consulted on strategies, product development, marketing, and management of the start-up company.</p>
</li>
        
      
    </ul>
  </div>
  <hr />









  <div id="education">
    <h2>Thomas O. Kleen, Ph.D.&#8217;s Education</h2>
    <ul class="vcalendar">
      
        

	<li class="education vevent vcard">
    <h3 class="summary fn org">
           Julius-Maximilians-Universit&#xe4;t W&#xfc;rzburg
      </h3>
		<div class="description">
    <p>
      <span class="degree">Doctorate</span>
        , 
      <span class="major">Immunology, Virology, Biology, Biochemistry</span>
      , 
          <abbr class="dtstart" title="2003-01-01">2003</abbr> &mdash; <abbr class="dtend" title="2004-12-31">2004</abbr> 
    </p>
      <p class="notes">Received a Ph.D. with &quot;magna cum laude&quot; from the Bayerische Julius-Maximilians-University W&#xfc;rzburg, Bavaria, Germany in 2004</p>
		<dl class="activities-societies">
			<dt>Activities and Societies:</dt>
			<dd>Activities:<br>
2008:	BioTechnology Industry Organization (BIO)-Licensing Executives Society (LES) Business Development Basics Course<br>
<br>
Societies:<br>
2008- Present:	International Society for Biological Therapy of Cancer (iSBTc)<br>
2004- Present: 	The American Association of Immunologists (AAI)</dd>
		</dl>
		</div>
  </li>

      
        

	<li class="education vevent vcard">
    <h3 class="summary fn org">
           Case Western Reserve University
      </h3>
		<div class="description">
    <p>
      <span class="degree">Ph.D. studies</span>
        , 
      <span class="major">Immunolgy, Virology, Biology, Biochemistry</span>
      , 
          <abbr class="dtstart" title="1999-01-01">1999</abbr> &mdash; <abbr class="dtend" title="2002-12-31">2002</abbr> 
    </p>
      <p class="notes">Investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections, which led to two peer reviewed publications in the immunology and infectious disease fields. <br>
<br>
Conducted research on the facilitation of umbilical cord blood stem cells for immune reconstitution of adult patients with life-threatening hematological disorders after treatment with full myelo-ablative regimens which resulted in two publications in peer reviewed journals in the fields of clinical immunology and transplantation.<br>
<br>
Gained extensive experience with state of the art immunological assays and equipment including FACS phenotyping,  thymidine incorporation assays as well as intracytoplasmic staining, cytokine ELISA&#x2019;s and chromium release assays while refining the cytokine and granzyme specific enzyme linked immunospot assays (ELISPOT) as a tool for immune-monitoring.</p>
		</div>
  </li>

      
        

	<li class="education vevent vcard">
    <h3 class="summary fn org">
           New Zealand Forest Research, Department of Molecular Genetics, Rotorua, New Zealand
      </h3>
		<div class="description">
    <p>
      <span class="degree">Research Scholar</span>
        , 
      <span class="major">Genetics</span>
      , 
          <abbr class="dtstart" title="1999-01-01">1999</abbr> &mdash; <abbr class="dtend" title="1999-12-31">1999</abbr> 
    </p>
      <p class="notes">Conducted research in the field of genetic engineering of plants, specifically the production, selection and expression of plasmids in plant cells.<br>
Cooperated in the introduction of pesticide resistance genes into the genome of commercial pine trees for later successful field trials</p>
		<dl class="activities-societies">
			<dt>Activities and Societies:</dt>
			<dd>1998-1999	M&#xfc;hlfenzel-Stipendium</dd>
		</dl>
		</div>
  </li>

      
        

	<li class="education vevent vcard">
    <h3 class="summary fn org">
           German Primate Center (DPZ), G&#xf6;ttingen, Germany
      </h3>
		<div class="description">
    <p>
      <span class="degree">M.S. studies</span>
        , 
      <span class="major">Immunology</span>
      , 
          <abbr class="dtstart" title="1998-01-01">1998</abbr> &mdash; <abbr class="dtend" title="1999-12-31">1999</abbr> 
    </p>
      <p class="notes">Investigated the immunogenicity of virus like particles (VLP's) in a rabbit model during the development of a new delivery method for gene therapy</p>
		</div>
  </li>

      
        

	<li class="education vevent vcard">
    <h3 class="summary fn org">
           Universit&#xe4;t Bremen
      </h3>
		<div class="description">
    <p>
      <span class="degree">M.S.</span>
        , 
      <span class="major">Biology</span>
      , 
          <abbr class="dtstart" title="1993-01-01">1993</abbr> &mdash; <abbr class="dtend" title="1999-12-31">1999</abbr> 
    </p>
      <p class="notes"></p>
		</div>
  </li>

      
    </ul>
  </div>
  <hr />












  <div id="additional-information">
    <h2>Additional Information</h2>
      <h3>Thomas O. Kleen, Ph.D.&#8217;s Websites:</h3>
      <ul class="websites">
          <li>
                <a href="http://www.immunospot.com" class="url" rel="nofollow" target="_blank">
                  My Company
                </a>
          </li>
      </ul>
      <h3>Thomas O. Kleen, Ph.D.&#8217;s Interests:</h3>
      <p class="interests">Pilot (single engine land), Scuba diving, snowboarding, international travel</p>
      <h3>Thomas O. Kleen, Ph.D.&#8217;s Groups:</h3>
        <p class="groups">
          iSBTc-FDA-NCI Biomarker Taskforce<br>
International Society for Biological Therapy of Cancer (iSBTc)<br>
The American Association of Immunologists (AAI)
        </p>
      <ul>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1426&amp;sharedKey=071A9163FFB8" >          <img src="http://media.linkedin.com/media/p/2/000/002/1c0/2899bc7.jpg" width="60" height="30" alt="Executive Suite" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Executive Suite</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=38734&amp;sharedKey=10B7C43CA183" >          <img src="http://media.linkedin.com/media/p/1/000/05f/396/1773016.png" width="60" height="30" alt="Pharmaceutical Business Development &amp; Licensing Network" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Pharmaceutical Business Development &amp; Licensing Network</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=57105&amp;sharedKey=19078420B30C" >          <img src="http://media.linkedin.com/media/p/3/000/019/28f/1f687ec.png" width="60" height="30" alt="Vaccines Development Forum" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Vaccines Development Forum</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=60035&amp;sharedKey=378558122A75" >          <img src="http://media.linkedin.com/media/p/1/000/00e/357/24afaec.png" width="60" height="30" alt="Biotech &amp; Pharma Professionals Network" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Biotech &amp; Pharma Professionals Network</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=117425&amp;sharedKey=5CC3203793EA" >          <img src="http://media.linkedin.com/media/p/2/000/035/245/13aa056.png" width="60" height="30" alt="Partnerships with CROs" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Partnerships with CROs</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=123422&amp;sharedKey=67D5C7610D8D" >          <img src="http://media.linkedin.com/media/p/1/000/00f/0d6/38d559b.png" width="60" height="30" alt="CRO and CMO, CRAMS (Contract Research/Development/Manufacturing Organizations) Professionals" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">CRO and CMO, CRAMS (Contract Research/Development/Manufacturing Organizations) Professionals</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=127165&amp;sharedKey=070F33555889" >          <img src="http://media.linkedin.com/media/p/3/000/021/342/3da685d.png" width="60" height="30" alt="BioSpace Biotechnology and Pharmaceutical Professionals group" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">BioSpace Biotechnology and Pharmaceutical Professionals group</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=981757&amp;sharedKey=06E8200F9E0C" >          <img src="http://media.linkedin.com/media/p/3/000/012/2ae/28a3fcc.png" width="60" height="30" alt="Partnerships in Clinical Trials" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Partnerships in Clinical Trials</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1085797&amp;sharedKey=7C475B34F292" >          <img src="http://media.linkedin.com/media/p/3/000/035/33d/070a4a2.png" width="60" height="30" alt="GAVI" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">GAVI</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1179467&amp;sharedKey=6D2FEE647650" >          <img src="http://media.linkedin.com/media/p/2/000/015/374/38a16c5.png" width="60" height="30" alt="Vaccine Knowledge Network" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Vaccine Knowledge Network</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1796473&amp;sharedKey=74DD471E97D8" >          <img src="http://media.linkedin.com/media/p/2/000/01b/323/025e778.png" width="60" height="30" alt="Biomarker Society" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Biomarker Society</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1821965&amp;sharedKey=4B09CB63CC81" >          <img src="http://media.linkedin.com/media/p/1/000/01d/316/0202137.png" width="60" height="30" alt="Immunogenicity for Biotherapeutics" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Immunogenicity for Biotherapeutics</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1865220&amp;sharedKey=6E8C48073298" >          <img src="http://media.linkedin.com/media/p/3/000/020/1a6/0236924.png" width="60" height="30" alt="Cell Based Assays" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Cell Based Assays</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1867992&amp;sharedKey=7C851E08EB34" >          <img src="http://media.linkedin.com/media/p/1/000/020/202/1b1c119.png" width="60" height="30" alt="Vaccine Manufacturers Network" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Vaccine Manufacturers Network</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1868035&amp;sharedKey=27C08A67B5CF" >          <img src="http://media.linkedin.com/media/p/2/000/021/223/3912712.png" width="60" height="30" alt="Vaccine Professionals Group" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Vaccine Professionals Group</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=1895301&amp;sharedKey=20A80F076A3A" >          <img src="http://media.linkedin.com/media/p/1/000/022/0d5/173c16d.png" width="60" height="30" alt="Alliance Management and Business Development Network" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">Alliance Management and Business Development Network</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=2077075&amp;sharedKey=4B4F3568660F" >          <img src="http://media.linkedin.com/media/p/1/000/029/2d1/158e1ae.png" width="60" height="30" alt="iSBTc (International Society for Biological Therapy of Cancer)" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">iSBTc (International Society for Biological Therapy of Cancer)</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=2788924&amp;sharedKey=76D4252308F1" >          <img src="http://media.linkedin.com/media/p/3/000/04c/0a0/1e57f10.png" width="60" height="30" alt="In vitro cellular assay in the Oncology, Immunology and Toxicology areas" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">In vitro cellular assay in the Oncology, Immunology and Toxicology areas</span> </li>
          <li class="affiliation vcard">
                <a href="http://www.linkedin.com/groupInvitation?groupID=2828186&amp;sharedKey=6FC1E73D5603" >          <img src="http://media.linkedin.com/media/p/3/000/04e/16a/087b432.png" width="60" height="30" alt="ImVacS -- the Immunotheraputics &amp; Vaccine Summit" class="logo" />
</a>&nbsp;&nbsp;
            <span class="fn org">ImVacS -- the Immunotheraputics &amp; Vaccine Summit</span> </li>
      </ul>
      <h3>Thomas O. Kleen, Ph.D.&#8217;s Honors:</h3>
      <p class="honors">
        Patents:<br>
<br>
Lehmann, P. V., Karulin, A. Y. and T. O. Kleen: Nanoparticle and Mircoparticle Based Detection of Cellular Products. 2008. <br>
<br>
Lehmann, P. V., Karulin, A. Y. Velasco Jr., V. B. and Kleen, T. O.: Instrumentation for Image Acquisition from Biological and Non-Biological Assays. Pub. No.: WO/2006/014925, International Application No.: PCT/US2005/026435, 2006<br>
<br>
Honors and Awards:<br>
<br>
1996-1998	Studienstiftung des Deutschen Volkes (German National Academic Foundation)*<br>
* The Studienstiftung des deutschen Volkes awards scholarships to intellectually outstanding students at universities and other institutions of higher education. The selection of students is based on their academic abilities, initiative and sense of social responsibility. The Studienstiftung supports ca. 6000 students, i.e. less than 0.3% of the current student population in Germany.  The Patron of the Studienstiftung des deutschen Volkes is the President of the Federal Republic of Germany.
      </p>
  </div>
  <hr />








  <div id="contact-settings">
    <h2>Thomas O. Kleen, Ph.D.&#8217;s Contact Settings</h2>
    <h3>Interested In:</h3>
    <ul>
      
        <li>
          career opportunities
        </li>
      
        <li>
          consulting offers
        </li>
      
        <li>
          new ventures
        </li>
      
        <li>
          job inquiries
        </li>
      
        <li>
          expertise requests
        </li>
      
        <li>
          business deals
        </li>
      
        <li>
          reference requests
        </li>
      
        <li>
          getting back in touch
        </li>
      
    </ul>
  </div>
  <hr />



        
      <div class="viewfull">
        <p><a href="http://www.linkedin.com/ppl/webprofile?vmi=&id=26894133&pvs=pp&authToken=vQDT&authType=name&locale=en_US&trk=ppro_viewmore&lnk=vw_pprofile" class="action" rel="nofollow"><span>View Full Profile</span></a></p>
      </div>
  </div>
  <div id="control" class="infobar">
    <div class="powered">
      <h3> Public profile powered by: <a href="/home?trk=ppro_pbli" ><img src="http://static.linkedin.com/scds/common/u/img/logos/logo_82x23.png" height="23" width="82" alt="LinkedIn" /></a>
      </h3>
      <p>Create a public profile: <strong>
        <a href="http://www.linkedin.com/ppl/webprofile?gwp=&id=26894133&pvs=pp&authToken=vQDT&authType=name&locale=en_US&trk=ppro_geturl&lnk=sign_in" rel="nofollow">Sign In</a>
        </strong> or <strong>
        <a href="http://www.linkedin.com/ppl/webprofile?gwp=&id=26894133&pvs=pp&authToken=vQDT&authType=name&locale=en_US&trk=ppro_joinnow&lnk=join_now" rel="nofollow">Join Now</a>
        </strong></p>
    </div>
      <div class="box" id="readmore">
        <div class="title">
          <h3>View Thomas O. Kleen, Ph.D.&#8217;s full profile:</h3>
        </div>
        <div class="content">
          <ul>
            <li>See who you and <strong>Thomas O. Kleen, Ph.D.</strong> know in common</li>
            <li>Get introduced to <strong>Thomas O. Kleen, Ph.D.</strong></li>
            <li>Contact <strong>Thomas O. Kleen, Ph.D.</strong> directly</li>
          </ul>
          <p class="btn">
            <a href="http://www.linkedin.com/ppl/webprofile?vmi=&id=26894133&pvs=pp&authToken=vQDT&authType=name&locale=en_US&trk=ppro_viewmore&lnk=vw_pprofile" class="action" rel="nofollow"><span>View Full Profile</span></a>
          </p>
        </div>
      </div>
    
    
    <div class="box" id="search">
      <div class="title">
        <h3><strong>Name Search:</strong></h3>
      </div>
      <div class="content">
        <p><strong>Search for people you know</strong> from over 70 million professionals already on LinkedIn.</p>
        <form name="searchForm" action="/pub/dir/" method="get">
          <p class="field"><span class="lbl">
            <label for="first">First Name</label>
            <br />
            </span>
            <input type="text" name="first" id="first" />
            &nbsp;&nbsp;<span class="lbl"><br />
            <label for="last">Last Name</label>
            <br />
            </span>
            <input type="text" name="last" id="last" />
          </p>
          <p class="example">
            <input class="btn-secondary" type="submit" name="search" value="Search"/> (example: <strong>
<a href="http://www.linkedin.com/in/jeffweiner08?trk=ppro_find_others_rh" >Jeff Weiner</a></strong>)
          </p>
        </form>
      </div>
    </div>
    
    <script type="text/javascript">
      var dbl_page = 'public_profile';
    </script>
    
      <script type="text/javascript" src="http://static.linkedin.com/scds/common/build-517_4_3411-prod/js/ads.js"></script>
    
      <script type="text/javascript">
      /* <![CDATA[ */
      var google_keywords = null, google_ad_client = 'pub-2283433109277150', google_ad_width = 300, google_ad_height = 250, google_ad_format = '300x250_as';
        var dbl_src = "http://ad.doubleclick.net/adj/linkedin.dart/" + dbl_page + ";;lang=en;tile=1;dcopt=ist;sz=300x250;" + encodeURIComponent('extra=null') + ";ord=" + Math.random() * 10000000000000000 +"?";
        document.write('<script src="' + dbl_src + '" type="text/javascript"><\/script>');
      /* ]]> */
      </script>
  </div>
</div>
<hr />







<div id="footer">
    <div id="directory">
      <h3>LinkedIn member directory:</h3>
      <ol type="a">
        <li><a href="/directory/people/a.html" >a</a></li>
        <li><a href="/directory/people/b.html" >b</a></li>
        <li><a href="/directory/people/c.html" >c</a></li>
        <li><a href="/directory/people/d.html" >d</a></li>
        <li><a href="/directory/people/e.html" >e</a></li>
        <li><a href="/directory/people/f.html" >f</a></li>
        <li><a href="/directory/people/g.html" >g</a></li>
        <li><a href="/directory/people/h.html" >h</a></li>
        <li><a href="/directory/people/i.html" >i</a></li>
        <li><a href="/directory/people/j.html" >j</a></li>
        <li><a href="/directory/people/k.html" >k</a></li>
        <li><a href="/directory/people/l.html" >l</a></li>
        <li><a href="/directory/people/m.html" >m</a></li>
        <li><a href="/directory/people/n.html" >n</a></li>
        <li><a href="/directory/people/o.html" >o</a></li>
        <li><a href="/directory/people/p.html" >p</a></li>
        <li><a href="/directory/people/q.html" >q</a></li>
        <li><a href="/directory/people/r.html" >r</a></li>
        <li><a href="/directory/people/s.html" >s</a></li>
        <li><a href="/directory/people/t.html" >t</a></li>
        <li><a href="/directory/people/u.html" >u</a></li>
        <li><a href="/directory/people/v.html" >v</a></li>
        <li><a href="/directory/people/w.html" >w</a></li>
        <li><a href="/directory/people/x.html" >x</a></li>
        <li><a href="/directory/people/y.html" >y</a></li>
        <li><a href="/directory/people/z.html" >z</a></li>
        <li type="disc"><a href="/directory/people/@.html" >more</a></li>
      </ol>
      <h3>Browse members</h3>
      <p>
        <a href="/static?key=country_listing" >by country</a>
      </p>
    </div>
  <div class="wrapper">
    <p id="copyright"><a href="http://www.linkedin.com/">LinkedIn</a> Corporation &copy; 2010</p>
    <ul id="nav-legal">
      <li><a href="/static?key=user_agreement&trk=ftr_useragre" rel="nofollow">User Agreement</a></li>
      <li><a href="/redirect?url=http%3A%2F%2Fpress%2Elinkedin%2Ecom%2Fabout&urlhash=ONnW" >About LinkedIn</a></li>
      <li class="last"><a href="/static?key=privacy_policy&trk=hb_ft_priv" >Privacy Policy</a></li>
    </ul>
    <p id="terms-of-use">
      Commercial use of this site without express authorization is prohibited.
    </p>
  </div>
</div>



  
  
  
  
  
   

        <script type="text/javascript" src="http://static.linkedin.com/scds/concat/common/build-517_4_3411-prod/js?f=lib%2Fyui%2F2.8.1%2Fyahoo-dom-event%2Fyahoo-dom-event&amp;f=js%2Fcore%2FDefine&amp;f=js%2Futil%2FHelps&amp;f=js%2Fpublic_profile&amp;f=js%2Fshowhide&amp;f=js%2Fcookies"></script>
    
<script type="text/javascript">
/* <![CDATA[ */
  if(typeof(i18n) == 'undefined') var i18n = {}; 
  i18n.TEXT_PLEASE_ENTER = "Please enter a first and last name.";
  showHide.init();

  var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
  document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
var pageTracker = _gat._getTracker("UA-3242811-1");
pageTracker._setDomainName(".linkedin.com"); 

pageTracker._linkedInMemberCookie = readCookie("visit"); 
pageTracker._linkedInUserType = (pageTracker._linkedInMemberCookie == "M") ? "user" : "guest";  
pageTracker._setVar(pageTracker._linkedInUserType);
    pageTracker._trackPageview("control_profiles");    
/* ]]> */
</script>


<script type="text/javascript" src="http://edge.quantserve.com/quant.js"></script> 
<noscript> 
  <a href="http://www.quantcast.com/p-b3sGjMtCFrexE" target="_blank"><img src="http://pixel.quantserve.com/pixel/p-b3sGjMtCFrexE.gif" style="display: none;" border="0" height="1" width="1" alt="Quantcast" /></a> 
</noscript>

<script type="text/javascript" src="http://b.scorecardresearch.com/beacon.js"></script> 
<script type="text/javascript">
  COMSCORE.beacon({ c1:2, c2:6402952, c3:"", c4:"", c5:"", c6:"", c15:"" });
</script>
<noscript> 
  <img src="http://b.scorecardresearch.com/b?c1=2&amp;c2=6402952&amp;c3=&amp;c4=&amp;c5=&amp;c6=&amp;c15=&amp;cv=1.3&amp;cj=1" style="display:none" width="0" height="0" alt="" />
</noscript>





<script type="text/javascript">/* <![CDATA[ */
(function() {
function readCookie(name) {
  var nameEQ = name + "=";
  var ca = document.cookie.split(';');
  for(var i = 0; i < ca.length; i++) {
    var c = ca[i];
    while (c.charAt(0)==' ') c = c.substring(1,c.length);
    if (c.indexOf(nameEQ) == 0) return c.substring(nameEQ.length,c.length);
  }
  return null;
}

if (typeof(XMLHttpRequest)  === "undefined") {
  XMLHttpRequest = function() {
    try { return new ActiveXObject("Msxml2.XMLHTTP.6.0"); } catch(e) {}
    try { return new ActiveXObject("Msxml2.XMLHTTP.3.0"); } catch(e) {}
    try { return new ActiveXObject("Msxml2.XMLHTTP"); }     catch(e) {}
    try { return new ActiveXObject("Microsoft.XMLHTTP"); }  catch(e) {}
    throw new Error("This browser does not support XMLHttpRequest.");
  };
}

var req = new XMLHttpRequest(),
    bcookie = escape(readCookie("bcookie")),
    url = '/analytics/noauthtracker?type=leo.pageTracking&pageType=full_page&pageKey=public_profile_jsbeacon&trackingInfo=26894133';

if (bcookie) {
req.open('get', url);
req.send(null);
}
})();
/* ]]> */</script>
</body>
</html>